Differences in perceived clinical knowledge uptake among health profession students and licensed clinicians receiving buprenorphine waiver training in Oregon

References

• Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy 2019;71:183–188.
   PubMed Web of Science ®Google Scholar
• Colon-Berezin C, Nolan ML, Blachman-Forshay J, Paone D. Overdose deaths involving fentanyl and fentanyl analogs – New York City, 2000–2017. MMWR Morb Mortal Wkly Rep. 2019;68(2):37–40.
   PubMed Web of Science ®Google Scholar
• Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574.
   PubMed Web of Science ®Google Scholar
• Ahmad FB, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts. Maryland: National Center for Health Statistics; 2021.
   Google Scholar
• Health NIo. NIH HEAL Initiative Research Plan. 2021.
   Google Scholar
• Luo F, Li M, Florence C. State-level economic costs of opioid use disorder and fatal opioid overdose – United States, 2017. MMWR Morb Mortal Wkly Rep. 2021;70(15):541–546.
   PubMed Web of Science ®Google Scholar
• Drug Overdose Deaths | Drug Overdose | CDC Injury Center. 2018.
   Google Scholar
• Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61–62.
   PubMed Web of Science ®Google Scholar
• Becker WC, Fiellin DA. When epidemics collide: Coronavirus Disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59–60.
   PubMed Web of Science ®Google Scholar
• Volkow ND, McLellan AT. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–1263.
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73–82.
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13(Suppl 1):S17–S28.
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
   PubMed Web of Science ®Google Scholar
• Federal Guidelines for Opioid Treatment Programs. https://store.samhsa.gov/product/Federal-Guidelines-for-Opioid-Treatment-Programs/PEP15-FEDGUIDEOTP. Published 2019. Accessed September 14, 2021.
   Google Scholar
• Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153–159.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Fiellin DA, Program U. Buprenorphine for office-based practice: consensus conference overview. Am J Addict. 2004;13 Suppl 1:S1–S7.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse. 2002;28(2):231–241.
   PubMed Web of Science ®Google Scholar
• Oregon Health Authority: Medication-Assisted Treatment and Recovery (U MATR): Addictions and Mental Health Services: State of Oregon. https://www.oregon.gov/oha/HSD/AMH/Pages/UMATR.aspx. Published 2019.
   Google Scholar
• Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff. 2015;34(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• NAABT I. DATA-2000 Full Law Text. https://www.naabt.org/data2000.cfm. Published 2019. Accessed September 14, 2021.
   Google Scholar
• Goldstein A. Biden administration eases restrictions on prescribing treatment for opioid addiction. The Washington Post 27/4/2021.
   Google Scholar
• Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. Jama 2019;321(14):1407–1408.
   PubMed Web of Science ®Google Scholar
• Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health 2021;2021:569.
   Google Scholar
• Lien IC, Seaton R, Szpytman A, et al. Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum. Med Educ Online. 2021;26(1):1847755.
   PubMed Web of Science ®Google Scholar
• Zerbo E, Traba C, Matthew P, et al. DATA 2000 waiver training for medical students: lessons learned from a medical school experience. Subst Abus 2020;2020:1–5.
   Google Scholar
• McCance-Katz EF, George P, Scott NA, Dollase R, Tunkel AR, McDonald J. Access to treatment for opioid use disorders: medical student preparation. Am J Addict. 2017;26(4):316–318.
   PubMed Web of Science ®Google Scholar
• Stokes DC, Perrone J. Increasing short- and long-term buprenorphine treatment capacity: providing waiver training for medical students. Acad Med 2021;2021:68.
   Google Scholar
• Riser E, Holterman LA, Maruti S, et al. Integrating DATA 2000 waiver training into undergraduate medical education: the time is now. Subst Abus 2021;2021:1–8.
   Google Scholar
• Auty SG, Stein MD, Walley AY, Drainoni ML. Buprenorphine waiver uptake among nurse practitioners and physician assistants: the role of existing waivered prescriber supply. J Subst Abuse Treat. 2020;115:108032.
   PubMed Web of Science ®Google Scholar
• Barnett ML, Lee D, Frank RG. In Rural Areas, buprenorphine waiver adoption since 2017 Driven by nurse practitioners and physician assistants. Health Aff. 2019;38(12):2048–2056.
   Web of Science ®Google Scholar
• Andrilla CHA, Patterson DG, Moore TE, Coulthard C, Larson EH. Projected contributions of nurse practitioners and physicians assistant to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2020;77(2):208–216.
   PubMed Web of Science ®Google Scholar
• Rose S. Medical student education in the time of COVID-19. JAMA 2020;323(21):2131–2132.
   PubMed Web of Science ®Google Scholar
• Ferrel MN, Ryan JJ. The impact of COVID-19 on medical education. Cureus 2020;12(3):e7492.
   PubMed Web of Science ®Google Scholar
• Tong ST, Hochheimer CJ, Peterson LE, Krist AH. Buprenorphine provision by early career family physicians. Ann Fam Med. 2018;16(5):443–446.
   PubMed Web of Science ®Google Scholar
• Andrilla CHA, Coulthard C, Patterson DG. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6 Suppl 3):S208–s214.
   PubMed Web of Science ®Google Scholar
• Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113–121.
   PubMed Web of Science ®Google Scholar
• Tesema L, Marshall J, Hathaway R, et al. Training in office-based opioid treatment with buprenorphine in US residency programs: a national survey of residency program directors. Subst Abus. 2018;39(4):434–440.
   PubMed Web of Science ®Google Scholar